INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

NCT03272464 PHASE1 TERMINATED Results posted

This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: * Itacitinib (INCB039110) * Dabrafenib * Trametinib

Details

Lead sponsor	Massachusetts General Hospital
Phase	PHASE1
Status	TERMINATED
Enrolment	1
Start date	Wed May 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Melanoma

Interventions

• Trametinib
• Dabrafenib
• INCB039110

Countries

United States